# AstraZeneca’s Tagrisso approved in China in early lung cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-tagrisso-approved-in-china-in-early-lung-cancer/412977292
- Published: 2021-04-14T07:26:02+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Tagrisso_ (osimertinib) has been approved in China for the adjuvant treatment of
patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated(
EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent,
with or without adjuvant chemotherapy as recommended by the patient’s physician.
_Tagrisso_ is indicated for EGFRm patients whose tumours have exon 19 deletions 
or exon 21 (L858R) mutations.

The approval by China’s National Medical Products Administration (NMPA) was based
on positive results from the ADAURA Phase III trial. In the trial, _Tagrisso_ demonstrated
a statistically significant and clinically meaningful improvement in disease-free
survival (DFS) in the primary analysis population of patients with Stage II and 
IIIA EGFRm NSCLC. The ADAURA trial also showed a statistically significant and clinically
meaningful improvement in DFS in the overall trial population of patients with Stage
IB-IIIA disease, a key secondary endpoint.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have
surgery with curative intent, recurrence is still common in early-stage disease.
Historically, nearly half of patients diagnosed in Stage IB, and over three quarters
of patients diagnosed in Stage IIIA, have experienced recurrence within five years.
^(1-3) More than a third of the world’s lung cancer patients are in China and among
those with NSCLC, approximately 40% have tumours with an EGFR mutation.^(4-6)

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said:** “
> The expedited approval of _Tagrisso_ in China as part of a curative-intent regimen
> for early-stage EGFR-mutated lung cancer underscores the high unmet need in this
> setting and our commitment to improving outcomes in a country with one of the 
> highest rates of EGFR mutations in the world. This approval reinforces the importance
> of EGFR testing across all stages of lung cancer, prior to treatment decisions,
> to ensure as many patients as possible can benefit from targeted therapies like
> _Tagrisso_ and live cancer-free longer.”

In the ADAURA trial, adjuvant treatment with _Tagrisso_ reduced the risk of disease
recurrence or death by 83% in patients with Stage II and IIIA disease (hazard ratio[
HR] 0.17; 99.06% confidence interval [CI] 0.11-0.26; p<0.001) and by 80% in the 
overall trial population of patients with Stage IB-IIIA disease (HR 0.20; 99.12%
CI 0.14-0.30; p<0.001).

Consistent DFS results were seen regardless of prior adjuvant chemotherapy use and
across all prespecified subgroups, including in Asian and non-Asian patients. The
safety and tolerability of _Tagrisso_ in this trial was consistent with previous
trials in the metastatic setting. The ADAURA results were published in The New England
Journal of Medicine.

_Tagrisso_ is approved to treat early-stage lung cancer in more than a dozen countries,
including the US, and additional global regulatory reviews are ongoing. _Tagrisso_
is also approved for the 1st-line treatment of patients with locally advanced or
metastatic EGFRm NSCLC and for the treatment of locally advanced or metastatic EGFR
T790M mutation-positive NSCLC in China, and in the US, Japan, the EU and many other
countries.

This approval follows a priority review designation by the NMPA’s Center for Drug
Evaluation. It marks the third approved indication for _Tagrisso_ in China following
previous approvals in 2nd-line T790M and 1st-line EGFRm NSCLC, which are both included
on the National Reimbursement Drug List.

**Lung cancer**

Lung cancer is the leading cause of cancer death among both men and women, accounting
for about one-fifth of all cancer deaths.^(4) Lung cancer is broadly split into 
NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.^(7 )The majority
of NSCLC patients are diagnosed with advanced disease while approximately 25-30%
present with resectable disease at diagnosis.^(1-2) Early-stage lung cancer diagnoses
are often only made when the cancer is found on imaging for an unrelated condition.
^(8-9)

For patients with resectable tumours, the majority of patients eventually develop
recurrence despite complete tumour resection and adjuvant chemotherapy.^(3)

Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients
in Asia have EGFRm NSCLC.^(10-12) These patients are particularly sensitive to treatment
with an EGFR-tyrosine kinase inhibitor (TKI) which blocks the cell-signalling pathways
that drive the growth of tumour cells.^(13)

**ADAURA**
ADAURA is a randomised, double-blind, global, placebo-controlled Phase
III trial in the adjuvant treatment of 682 patients with Stage IB, II and IIIA EGFRm
NSCLC following complete tumour resection and adjuvant chemotherapy as indicated.
Patients were treated with _Tagrisso_ 80mg once-daily oral tablets or placebo for
three years or until disease recurrence.

The trial enrolled patients in more than 200 centres across more than 20 countries,
including the US, in Europe, South America, Asia and the Middle East. The primary
endpoint was DFS in Stage II and IIIA patients and a key secondary endpoint was 
DFS in Stage IB, II and IIIA patients.

The data readout was originally anticipated in 2022. In April 2020, an Independent
Data Monitoring Committee recommended for the trial to be unblinded two years early
based on a determination of overwhelming efficacy. Investigators and patients continue
to participate and remain blinded to treatment. The trial will continue to assess
overall survival.

**_Tagrisso_**
_Tagrisso_ (osimertinib) is a third-generation, irreversible EGFR-
TKI with clinical activity against central nervous system metastases. _Tagrisso_(
40mg and 80mg once-daily oral tablets) has been used to treat approximately 250,000
patients across indications worldwide and AstraZeneca continues to explore _Tagrisso_
as a treatment for patients across multiple stages of EGFRm NSCLC.

In Phase III trials, _Tagrisso_ is being tested in the Stage III locally advanced
unresectable setting (LAURA), in the neoadjuvant resectable setting (NeoADAURA) 
and in combination with chemotherapy (FLAURA2). AstraZeneca is also researching 
ways to address tumour mechanisms of resistance through the SAVANNAH and ORCHARD
Phase II trials, which test _Tagrisso_ given concomitantly with savolitinib, an 
oral, potent and highly selective MET TKI, as well as other potential new medicines.

Share on:
